Led · Series B · Dec 2022

Trilio provides cloud-native data protection and management, with its TrilioVault technology used for backup and recovery, migration, ransomware protection and application mobility. The product targets cloud architects and DevOps engineers supporting applications on Kubernetes and OpenStack. Customers span telecom, defense, automotive and financial services and use TrilioVault for migration, rapid ransomware recovery and disaster recovery compliance. The company said it will use new funding to increase focus on product development, engineering and customer operations. Leadership includes CEO Massood Zarrabian; David Safaii has transitioned to Executive Chairman and Christina Lattuca joined as CFO and VP of Operations. The company is based in Framingham, MA and has raised a total of $36M to date. Trilio's core product is TrilioVault, a cloud-native data protection platform for Kubernetes, OpenStack and Red Hat Virtualization that supports backup and recovery, migration, DR and application mobility. The company recently released TrilioVault for Kubernetes v2.0, including a multi-cloud management console, and achieved Red Hat OpenShift Operator certification. Trilio serves customers in telecom, defense, automotive and financial services and reported 300%+ growth in 1H 2020. The company plans to use new funding to expand go-to-market capabilities and accelerate adoption across hybrid- and multi-cloud markets. Trilio will further invest in product development, sales, marketing and customer success to bring TrilioVault to markets across the globe. Leadership highlighted the platform's fit for Kubernetes-era data management challenges and the company has received recognition from GigaOm and Gartner. Trilio Data, founded in 2013 and based in Boston, provides a business assurance platform for IT organizations and cloud service providers deploying application workloads in public, private and hybrid clouds. Its flagship product, TrilioVault, is a data backup and recovery solution for OpenStack adopters that supports data protection, migration, resource management, configuration, change management, and sandbox-as-a-service. The company is led by CEO David Safaii. Trilio intends to use the funds to grow its engineering, sales and marketing teams and to increase channel enablement support for its global customer base. The company’s core focus is protecting and managing application workloads across cloud environments.

Participated · Series B · Jan 2022

Windgap Medical develops patient solutions built on a patented wet/dry drug-delivery platform and autoinjector technology. Its lead program is an epinephrine autoinjector for the treatment of anaphylaxis, for which the company intends to seek FDA approval. Windgap is also advancing a novel emergency treatment for cyanide poisoning sponsored by the National Institutes of Health through a multi-year CounterACT grant led by the University of Minnesota Twin Cities. The company said it will use new funding to energize the ongoing epinephrine commercialization process and grow its pipeline of additional products that utilize the platform. Windgap’s products have not been reviewed by the FDA to date. The company is led by CEO Christopher Stepanian and CTO Brent Buchine, PhD, and is based in Watertown, MA. Windgap Medical develops a patented wet/dry drug-delivery platform. Its first product is designed for administration of epinephrine to treat anaphylaxis, and the company has additional products under development in other markets. None of Windgap’s products have been reviewed by the FDA; the company intends to seek FDA approval first for the epinephrine product. The company is led by CEO and co-founder Chris Stepanian and is based in Watertown, Massachusetts. Financially, Windgap received a strategic investment of undisclosed size. The investment was led by Shepherd Kaplan Krochuck, with participation from Molex Ventures (a subsidiary of Koch Industries). Windgap Medical is developing a smaller, more user-friendly epinephrine auto-injector with a dry, more temperature-stable formulation intended to be pocket-sized (about the size of a Bic lighter). The device is designed to make it obvious which end is the needle and to reduce user errors common with current auto-injectors. Windgap holds more than a dozen provisional patents and has patents pending covering device design and the drug formulation. The company is targeting a market release by 2018 and intends to compete in the roughly $1.3 billion auto-injector market dominated historically by the EpiPen (with >90% market share). Windgap positions its product against competitors such as Sanofi’s Auvi-Q and upcoming generic alternatives and has not disclosed pricing or reimbursement plans, leaving that to commercialization partners. The startup was a 2012 MassChallenge winner and has raised financing to support development.

Led · Series A · Jun 2021

Etiometry develops decision‑support software for intensive care clinicians that aggregates vital signs from multiple sources into a single platform to surface evolving clinical risk. The company’s tools are used in more than 20 of the top U.S. children’s hospitals and have been adopted in several adult ICUs at leading U.S. medical centers. Etiometry has obtained multiple FDA 510(k) clearances (six as of 2020) and anticipated a seventh clearance in the second half of 2021 for new risk algorithms. Founded in 2010 and operating out of Boston, the company emphasizes building clinical evidence and refining the predictive models that power its software. Future plans described in the articles include extending use of the platform to other hospital care settings, accelerating R&D, and expanding clinical initiatives and commercial reach. The company recently expanded its leadership team to support scaling sales, strategy, and finance functions.

Led · Series C · Jul 2020

NanoDiagnostics (BioDirection, Inc.) is a Boston-based medical device company developing point-of-care in-vitro diagnostic products using its NanoDx nanotechnology platform. NanoDx can identify and quantify blood biomarkers from a drop of blood in less than two minutes for point-of-care, point-of-injury, or remote testing. The company is targeting applications including objective detection, diagnosis and management of traumatic brain injury (TBI), virus detection, and inflammatory disease. NanoDiagnostics received FDA Breakthrough Device designation in January 2019 for its first application as a screen to CT scans for suspected mild TBI. It closed an $18M Series C on Jan. 7, 2020 led by the Alternative Investment division of Shepherd Kaplan Krochuk (SKK); proceeds will support final product validation, scale-up of NanoDx System manufacturing, and initial product introductions in the US and European markets in 2020. Subject to FDA clearance it plans a U.S. launch later in 2020, anticipates entering the European market in Summer 2020, and is also developing a rapid SARS-CoV-2 antigen test from a drop of blood or saliva on the same platform. BioDirection is a Boston, MA-based medical device company focused on rapid point-of-care products for objective management of concussion and other traumatic brain injury (TBI). Its core product is Tbit, a technology platform that uses a patented nanotechnology biosensor to rapidly detect and measure protein biomarkers released from the brain immediately following head trauma. Tbit is designed to enable testing at the earliest stages of medical diagnosis and intervention. The company expects to use recent funding to accelerate execution of the final stages of development and plans for commercialization of the Tbit system. BioDirection closed over $4M in a Series B financing and has raised approximately $10M in total funding to date. The company is led by president and CEO Eric Goorno. BioDirection develops portable, low-cost point-of-care biomarker devices for screening and monitoring brain injury built around its Tbit™ biosensor test platform. The company uses nano biosensor technology to identify biomarkers released from the brain after traumatic injury and can generate a test result in 60–90 seconds from a single drop of blood. BioDirection is privately held and completed a $3.95 million Series A financing to fund product development and miniaturization. Funds will be used to finish two Tbit operating systems: a bench-top chemical test system and a handheld unit. The company planned a bench-top launch in November of the year reported and a handheld launch in the first quarter of 2014. BioDirection emphasizes early identification and rapid testing to address gaps in symptom-based diagnosis and enable earlier medical intervention.